News Adaptimmune revives ovarian cancer trial T-cell trial will include controversial chemo agent fludarabine.
News Adaptimmune progresses T-cell therapy trial Biotech says "robust" clinical response in early stage trial.
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
News Neuralink gets okay for its first international trial Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
